← Back
Data updated: Mar 10, 2026
CHARTWELL INJECTABLE
RespiratoryInfectious DiseaseCardiovascular
CHARTWELL INJECTABLE is a generic drug manufacturer focused on Respiratory, Infectious Disease, Cardiovascular.
1997
Since
6
Drugs
-
Trials
8
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
PROPRANOLOL HYDROCHLORIDE 2026-01-27
PROPRANOLOL HYDROCHLORIDE 2025-05-08
Labeling
ACYCLOVIR SODIUM 2025-02-18
Labeling
PROPRANOLOL HYDROCHLORIDE 2024-10-09
Labeling
PROPRANOLOL HYDROCHLORIDE 2024-08-23
Labeling
PROPRANOLOL HYDROCHLORIDE 2024-07-11
Labeling
ACYCLOVIR SODIUM 2024-06-25
ACYCLOVIR SODIUM 2024-03-28
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Respiratory 40%
2 drugs
Infectious Disease 20%
1 drugs
Cardiovascular 20%
1 drugs
Neurology 20%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Respiratory
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Respiratory
GSK big-pharma
Infectious Disease, Respiratory, Neurology
APOTHECON specialty
Infectious Disease, Cardiovascular, Respiratory
ACTELION big-pharma
Cardiovascular, Respiratory, Neurology, Infectious Disease
Discontinued (2)
Company Info
- First Approval
- 1997-04-22
- Latest
- 2011-04-08
- Applications
- 6